4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
Molecular Partners AG (NASDAQ:MOLN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...
New S32K5 microcontroller family advances zonal SDV architectures and extends the NXP CoreRide platform
New family of MCUs helps automakers shift to SDVs with a range of zonal and electrification architecturesCombines leading-edge core performance ...
4D Molecular Therapeutics, Inc.: 4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...
01Net10d
MWC 2025: Intel Showcases Foundational Network Infrastructure with Xeon 6
By integrating AI acceleration with Intel® Advanced Vector Extensions (AVX ... and commercial AI PC solutions. Intel (Nasdaq: ...
4DMT to Participate in Upcoming Investor Conferences
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage company focused on unlocking the full potential of genetic medicines to treat large market diseases, today ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...
Kratos Awarded Potential $50 Million Short/Medium Range Sub-Orbital Vehicle II Contract to Support Missile Defense Related Missions
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security, and global markets, today announced the award of the Short/Medium Range Sub-Orbital ...
Business Insider13d
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
Transaction Details Pacira intends to maintain GQ Bio’s operations and invest in its HCAd gene therapy vector platform and innovative products built on the platform, leveraging Pacira’s clinical, ...
Business Insider8d
Nasdaq Reports February 2025 Volumes
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for February 2025 on its Investor Relations website. A data sheet showing this information can be ...
Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...